论文部分内容阅读
目的初步探讨血管内皮抑素(ES)腹腔内给药治疗恶性腹腔积液的治疗机制。方法健康BABL/C小鼠,应用S180细胞建立腹腔积液模型。ES分为5.00mg/kg、2.50mg/kg及1.25mg/kg三组;阴性对照组为生理盐水组;阳性对照组为60.00mg/kg顺铂组。S180细胞腹腔注射接种5d后,实验药物隔日腹腔注射。记录小鼠体重作为腹水计量变化指标。计数小鼠存活只数计算存活率。结果 ES治疗癌性腹水的实验结果显示实验各组间小鼠体重具有统计学差异,高剂量组具有明显的优势,并且与顺铂对照组相当,组间比较具有统计学差异(P<0.05)。ES对恶性腹水小鼠存活率的影响提示,除低剂量组与中剂量组之间无统计学差异外,其余各组间均有统计学差异(P<0.05);不同时间存活率各组间比较均有统计学差异(P<0.01)。综合分析结果显示:在各实验组中,低剂量治疗组小鼠存活率显著高于其他各治疗组,低剂量组小鼠,存活时间长。结论重组人ES具有较好的抗肿瘤性腔内积液效果,并可延长腹水小鼠的生存时间,提高生存率。
Objective To investigate the therapeutic mechanism of endostatin (ES) administered intraperitoneally to treat malignant ascites. Methods Healthy BABL / C mice were treated with S180 cells to establish a model of ascites. ES divided into three groups of 5.00mg / kg, 2.50mg / kg and 1.25mg / kg; negative control group was saline group; positive control group was 60.00mg / kg cisplatin group. S180 cells were injected intraperitoneally 5d after injection of the experimental drugs every other day. Record body weight of mice as a measure of changes in ascites. Survival rates were calculated by counting the number of mice surviving. Results The results of esophageal squamous cell carcinoma treated with esophageal cancer showed that there was a significant difference in the body weight between the two groups. The high dose group had obvious advantages and was comparable with cisplatin control group, with statistical significance (P <0.05) . The effect of ES on the survival rate of mice with malignant ascites showed that except the low-dose group and middle-dose group, there was no significant difference (P <0.05). The survival rates of different groups The differences were statistically significant (P <0.01). Comprehensive analysis showed that: in each experimental group, low-dose treatment group mice survival was significantly higher than the other treatment groups, low-dose group of mice, long survival time. Conclusion Recombinant human ES possesses good anti-tumor effusion effect and prolongs the survival time of ascites mice and improves the survival rate.